IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
Critical priority
The issue
New safety information - Product safety
Affected product
IMBRUVICA (ibrutinib), 140 mg, 280 mg, 420 mg and 560 mg tablets, and 140 mg capsules
Where it was sold
Canada (national)Reported in the official notice — confirm there.
Issued by
Health Canada — Marketed health products
Read the official Government of Canada notice
All recallsRecallGuardian ranks, illustrates and rewrites recalls in plain language. The official notice is authoritative — confirm model numbers, lot codes, dates and remedies there.